ARCHOS announces a resounding success for its capital increase

ARCHOS recently closed a capital increase, launched on April 9, 2024, with an impressive oversubscription of 190.6%. This financial transaction marks the end of the company's dilutive financing instruments. The group reveals that management now holds more than 25% of the quorum of the 58,053,021 shares in circulation.

The group is currently focusing on its three-year strategic plan 2024-2026. This plan aims for profitable growth via three main market pillars: general public, professional and medical. The financial objective for 2024 is to reach 40 million euros in turnover with a profitable EBITDA, and to surpass 50 million euros in 2025. ARCHOS also plans to launch, at Christmas 2024, a new range of solutions dedicated to the health and well-being of pets and continues to invest in defense technology.

The company also mentions collaborations with start-ups, notably DOMISANTE, for monitoring vital signs at home. With a cash position exceeding 10 million euros, ARCHOS does not exclude the possibility of external growth in sectors with high added value.

The publication of the unaudited turnover is scheduled for July 18 after market close, followed by the publication of the half-year accounts on August 8, 2024.